Prescription drug · NDA AUTHORIZED GENERIC
Sucralfate NDC 80425-0213
Sucralfate 1 g/1 · Tablet · Oral · Advanced Rx Pharmacy of Tennessee, LLC
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 80425-0213-1 | 80425021301 | 30 TABLET in 1 BOTTLE (80425-0213-1)Marketed from Jan 3, 2023 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Sucralfate
- Generic name (nonproprietary)
- sucralfate
- Active ingredients
- Sucralfate — 1 g/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA authorized genericApplication NDA 018333
- Marketing start
- Listing expires
- Other FDA classes
- Organometallic Compounds (Chemical structure)
- Identifiers
- Product ID 80425-0213_2a9a6113-0a2f-6005-e063-6294a90abc5eSPL ID 2a9a6113-0a2f-6005-e063-6294a90abc5eSPL set ID f15fbb45-4406-0d32-e053-2995a90a40c5RxCUI 314234UNII XX73205DH5
- Pharmacologic class
- Aluminum Complex
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N480425021301followed by a unit qualifier and the quantityPackage 80425-0213-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Indications and Usage Sucralfate is indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 018333
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Northwind Health Company, LLC | 51655-475 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Aphena Pharma Solutions - Tennessee, LLC | 71610-017 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Bryant Ranch Prepack | 71335-2637 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Preferred Pharmaceuticals Inc. | 68788-8316 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Mylan Pharmaceuticals, Inc. | 59762-0401 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | Advanced Rx Pharmacy of Tennessee, LLC | 80425-0377 |
| Carafatesucralfate | Sucralfate 1 g/1 | TabletOral | Allergan, Inc. | 58914-171 |
| Sucralfate | Sucralfate 1 g/1 | TabletOral | A-S Medication Solutions | 50090-5287 |